Role of Kinins in the Cardioprotective Effect of Preconditioning: Study of Myocardial Ischemia/Reperfusion Injury in B2 Kinin Receptor Knockout Mice and Kininogen-Deficient Rats

Hypertension

Volumn 30, Issue 3, 1997, Pages 735-740

  Yang, Xiao Ping ^a   Liu, Yun He ^a   Scicli, Gloria M ^a   Webb, Charles R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; KININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; KALLIKREIN KININ SYSTEM; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANIMALS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; KININOGENS; MALE; MICE; MICE, KNOCKOUT; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, INBRED BN; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ;

EID: 0030753323     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.30.3.735     Document Type: Article

References (46)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136.
2. Lawson CS, Downey JM. Preconditioning: state of the art myocardial protection. Cardiovasc Res. 1993;27:542-550.
3. Toombs CF, Moore TL, Shebuski RJ. Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. Cardiovasc Res. 1993;27:617-622.
4. Yellon DM, Alkhulaifi AM, Browne EE, Pugsley WB. Ischaemic preconditioning limits infarct size in the rat heart. Cardiovasc Res. 1992;26:983-987.
5. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW Jr, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation. 1990;82:2044-2051.
6. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet. 1993;342:276-277.
7. 1 adenosine receptors in rabbit heart. Circulation. 1991;84:350-356.
8. 1-adenosine receptors. Am J Physiol. 1989;257:H1952-H1957.
9. Knowlton AA, Brecher P, Apstein CS. Rapid expression of heat shock protein in the rabbit after brief cardiac ischemia. J Clin Invest. 1991;87:139-147.
10. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 1994;266:H1145-H1152.
11. Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C. Its role in ischemic preconditioning in the rat. Circ Res. 1994;75:586-590.
12. Menasche P, Kevelaitis E, Mouas C, Grousset C, Piwnica A, Bloch G. Preconditioning with potassium channel openers. A new concept for enhancing cardioplegic protection? J Thorac Cardiovasc Surg. 1995;110:1606-1613.
13. Parratt JR, Vegh A, Papp JG. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning: a brief review of the evidence. Can J Physiol Pharmacol. 1995;73:837-842.
14. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res. 1993;27:334-340.
15. Tio RA, van Gilst WH, Rett K, Wolters K, Dietze GJ, Wesseling H. The effects of bradykinin and the ischemic isolated rat heart. Horm Metab Res Suppl. 1990;22:85-89.
16. Linz W, Wiemer G, Scholkens BA. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Diabetes. 1996;45(suppl 1):S51-S58.
17. Rubin LE, Levi R. Protective role of bradykinin in cardiac anaphylaxis. Coronary-vasodilating and antiarrhythmic activities mediated by autocrine/paracrine mechanisms. Circ Res. 1995;76:434-440.
18. Wall TM, Farrell AL, Hartman JC. The temporal relationship between bradykinin and KATP channels in the mechanism of cardioprotective ischemic preconditioning. Circulation. 1995;92(suppl I):I-252. Abstract.
19. Brew EC, Mitchell MB, Rehring TF, Gamboni-Robertson F, McIntyre RC Jr, Harken AH, Banerjee A. Role of bradykinin in cardiac functional protection after global ischemia-reperfusion in rat heart. Am J Physiol. 1995;269:H1370-H1378.
20. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 1994;270:681-689.
21. Peiro C, de Sagarra MR, Redondo J, Sanchez-Ferrer CF, Marin J. Vascular smooth muscle proliferation in hypertensive transgenic rats. J Cardiovasc Pharmacol. 1992;20(suppl 12):S128-S131.
22. Regoli D. Pharmacology of bradykinin and related kinins. Adv Exp Med Biol. 1983;156:569-584.
23. Regoli D, Rhaleb NE, Drapeau G, Dion S, Tousignant C, D'Orleans-Juste P, Devillier P. Basic pharmacology of kinins: pharmacologic receptors and other mechanisms. Adv Exp Med Biol. 1989;247:399-407.
24. 2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem. 1995;270:13706-13710.
25. 2 receptor knockout mice. Biochem Biophys Res Commun. 1996;224:625-630.
26. Yang X-P, Sabbah HN, Liu Y-H, Sharov VG, Mascha EJ, Alwan I, Carretero OA. Ventriculographic evaluation in three rat models of cardiac dysfunction. Am J Physiol. 1993;266:H1946-H1952.
27. Majima M, Katori M, Hanazuka M, Mizogami S, Nakano T, Nakao Y, Mikami R, Uryu H, Okamura R, Mohsin SSJ, Oh-Ishi S. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension. 1991;17:806-813.
28. Scicli AG, Mindroiu T, Scicli G, Carretero OA. Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin Med. 1982;100:81-93.
29. Carretero OA, Scicli AG. The kallikrein-kinin system as a regulator of cardiovascular and renal function. In: Laragh JH, Brenner BM, eds. Hypertension: Physiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995;983-999.
30. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG. A local kallikrein-kinin system is present in rat hearts. Hypertension. 1994;23:919-923.
31. Nolly H, Carretero OA, Scicli AG. Kallikrein release by vascular tissue. Am J Physiol. 1993;265:H1209-H1214.
32. Caroff N, Della Bruna R, Philippe J, Corvol P, Pinet F. Regulation of human renin secretion and renin transcription by quantitative PCR in cultured chorionic cells: synergistic effect of cyclic AMP and protein kinase C. Biochem Biophys Res Commun. 1993;193:1332-1338.
33. Dreyer WJ, Michael LH, West MS, Smith CW, Rothlein R, Rossen RD, Anderson DC, Entman ML. Neutrophil accumulation in ischemic canine myocardium. Insights into time course, distribution, and mechanism of localization during early reperfusion. Circulation. 1991;84:400-411.
34. Go LO, Murry CE, Richard VJ, Weischedel GR, Jennings RB, Reimer KA. Myocardial neutrophil accumulation during after reversible and irreversible ischemic injury. Am J Physiol. 1988;255:H1188-H1198.
35. Liu Y-H, Yang X-P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 1996;27:7-13.
36. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995;77:611-621.
37. Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning of the ischaemic myocardium involve cyclo-oxygenase products. Cardiovasc Res. 1990;24:1020-1023.
38. Zhang X, Xie Y-W, Nasjletti A, Xu X, Wolin MS, Hintze TH. ACE inhibitors promote nitric oxide accumulation to modulate oxygen consumption. Circulation. 1997;95:176-182.
39. Schoelkens BA, Linz W. Bradykinin-mediated metabolic effects in isolated perfused rat hearts. Agents Actions Suppl. 1992;38:36-42.
40. Rett K, Wicklmayr M, Dietze GJ, Haring HU. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes. 1996;45(suppl 1):S66-S69.
41. Dietze G, Maerker E, Lodri C, Schifman R, Wicklmayr M, Geiger R, Fink E, Boettger I, Fritz H, Mehnert H. Possible involvement of kinins in muscle energy metabolism. Adv Exp Med Biol. 1984;167:63-71.
42. Hartl WH, Jauch KW, Wolfe RR, Schildberg FW. Effects of kinins on glucose metabolism in vivo. Horm Metab Res Suppl. 1990;22:79-84.
43. Rett K, Maerker E, Lodri C, Wicklmayr M, Dietze G. Effects of kallikrein (K), bradykinin (B) and insulin (I), on substrate metabolism in the isolated perfused rat heart. Adv Exp Med Biol. 1986;198:379-384.
44. Yang X-P, Liu Y-H, Peterson E, Carretero OA. Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury. The role of kinins. J Cardiovasc Pharmacol. 1997;29:250-256.
45. Chan HW-S, Newby VK. Haemoprotein- and transition metal ion-catalysed oxidation of linoleic acid. Selectivity of the position of oxygenation. Biochim Biophys Acta. 1980;617:353-362.
46. Linz W, Martorana PA, Scholkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol. 1990;15(suppl 6):S99-S109.